SCHEMBL55883

SCHEMBL55883

CCCC#CCCCCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.52
HMGCR P04035 2/20 0.52
RECQL P46063 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
MCL1 Q07820 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 2/20 0.44
THRB P10828 1/20 0.44
EPHX2 P34913 3/20 0.41
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9836895 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL514093 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015828 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015881 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015929 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015897 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015933 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9943966 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL512606 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E
SCHEMBL9015878 0.97 PTPN7 (0.56) PTPN7HMGCRRECQLTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS FLAGSHIP LABS 114, INC. (US) 2026-05-14 US claimed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP claimed
WO-2024211865-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY OMEGA THERAPEUTICS, INC. (US) 2024-10-10 WO claimed
US-20240298681-A1 METHODS AND COMPOSITIONS FOR AFFECTING THE FLAVOR AND AROMA PROFILE OF CONSUMABLES IMPOSSIBLE FOODS INC. 2024-09-12 US claimed
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
WO-2023225621-A2 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS OMEGA THERAPEUTICS, INC. (US) 2023-11-23 WO claimed
EP-3642211-B1 ALDIMINOSILANES SIKA TECH AG (CH) 2023-04-05 EP claimed
EP-3642252-B1 LATENT CURING AGENT AND CURABLE POLYURETHANE COMPOSITION SIKA TECH AG (CH) 2021-12-08 EP claimed
US-11013250-B2 Methods and compositions for consumables IMPOSSIBLE FOODS INC. (US) 2021-05-25 US claimed
US-10993462-B2 Methods and compositions for consumables IMPOSSIBLE FOODS INC. (US) 2021-05-04 US claimed
CN-108130127-B Treatment method of reaction waste gas generated in synthesis of isoprene by olefine aldehyde gas phase method 中国科学院长春应用化学研究所 2020-12-08 CN claimed
US-20190200658-A1 METHODS AND COMPOSITIONS FOR CONSUMABLES IMPOSSIBLE FOODS INC. 2019-07-04 US claimed
US-20190116855-A1 METHODS AND COMPOSITIONS FOR CONSUMABLES IMPOSSIBLE FOODS INC. 2019-04-25 US claimed
US-9568821-B2 Patterning process SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-02-14 US claimed
US-9507262-B2 Resist top-coat composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-29 US claimed
EP-2943072-A2 METHODS AND COMPOSITIONS FOR AFFECTING THE FLAVOR AND AROMA PROFILE OF CONSUMABLES Impossible Foods Inc. (US) 2015-11-18 EP claimed
US-20150234278-A1 PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
US-20150234274-A1 RESIST TOP-COAT COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2015-08-20 US claimed
WO-2014110532-A2 METHODS AND COMPOSITIONS FOR AFFECTING THE FLAVOR AND AROMA PROFILE OF CONSUMABLES MARAXI, INC. (US) 2014-07-17 WO claimed
EP-2181763-B1 Catalyst and process for alkoxylation SHELL INT RESEARCH (NL) 2012-06-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130860-A1 LIPIDS FOR DELIVERY OF THERAPEUTIC AGENTS NSUN3, NSUN2, LDLR PTPN7 2194/4885HMGCR 460/4885RECQL 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.